Human Beta-Defensin 3 Induces Maturation of Human Langerhans Cell–Like Dendritic Cells: An Antimicrobial Peptide that Functions as an Endogenous Adjuvant  by Ferris, Laura K. et al.
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of Human Langerhans Cell–Like Dendritic Cells:
An Antimicrobial Peptide that Functions as an
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Robert L. Ferris2,3,4 and Louis D. Falo Jr1,4
Human beta-defensins (hBDs) are antimicrobial peptides that have an important role in innate immune
responses at epithelial barriers such as the skin. However, the role that hBDs have in initiating cellular immune
responses that contribute to antigen-specific adaptive immunity is not well understood. Here we show that one
member of the hBD family, hBD3, can induce maturation and T-helper type 1 skewing function in human
Langerhans cell–like dendritic cells (LC-DCs). Specifically, hBD3 potently induces phenotypic maturation of
LC-DCs, including increased expression of CCR7, which mediates functional chemotactic responses to CCL19
and CCL21. hBD3-stimulated LC-DCs induce strong proliferation of and IFN-g secretion by naive human T cells.
hBD3 also induces phenotypic maturation of primary human skin–migratory DCs derived from human skin
explants. These results suggest an important role for hBD3 in inducing DC activation, migration, and
polarization. Thus, hBD3 contributes to the integration of innate and adaptive immune responses in the skin,
and may be a useful adjuvant for skin immunization and an important factor in the pathophysiology of
inflammatory skin diseases.
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INTRODUCTION
Antimicrobial peptides such as human beta-defensins (hBD1-
4) and cathelicidins are produced in a variety of epithelial
tissues, with particularly high expression in inflamed skin.
They are capable of killing pathogens that breach surface
barriers, providing a primitive but critical function in host
defense. Indeed, their expression is induced in the skin under
conditions of inflammation, infection, and wound healing
because of the secretion of various pathogenic stimuli and
cytokines. For instance, increased expression of hBD2 has
been directly associated with stimulation by tumor necrosis
factor (TNF)-a, IL-1, lipopolysaccharide (Liu et al., 2002),
flagellin (Gerstel et al., 2009), and IL-22 (Wolk et al., 2004).
The increased expression of hBD3 is associated with
stimulation by IL-22 (Wolk et al., 2004), transforming growth
factor (TGF)-a alone, or in combination with insulin-like
growth factor I (Sorensen et al., 2003), stimulation of Toll-like
receptor (TLR)-2 (Menzies and Kenoyer, 2006), and IFN-g
(Joly et al., 2005).
In addition to their antimicrobial functions, BDs may
contribute to the induction of acquired immune responses by
recruiting monocytes, dendritic cells (DCs), and T cells to
sites of inflammation (Territo et al., 1989; Oppenheim et al.,
2003; Larregina and Falo, 2005; He et al., 2006). In previous
studies, hBD2 and/or hBD3 have been implicated in the
chemotaxis of immature DCs and T cells through their
interactions with chemokine receptor 6 (CCR6) and the
chemotaxis of monocytes through their interactions with
CCR2 (Rohrl et al., 2010). In addition, hBD3 has been shown
to induce the expression of various costimulatory molecules
on monocytes and myeloid DCs through its interactions
with TLRs 1 and 2 (Funderburg et al., 2007). Interestingly,
antimicrobial peptides can mediate either induction or
inhibition of DC activation, depending on experimental
conditions. In mice, murine beta-defensin 2 (mBD2) has
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been shown to promote the maturation of DC via TLR4, the
receptor for bacterial lipopolysaccharide (Biragyn et al.,
2002). The human cathelicidin LL-37 has been shown to
induce DC maturation in vitro (Davidson et al., 2004).
Conversely, cathelicidins have been shown to block TLR4-
mediated DC activation and inhibit allergic contact sensiti-
zation in mice (Di Nardo et al., 2007). Both BDs and
cathelicidins have been implicated in the pathogenesis of
inflammatory skin diseases. Indeed, the expression of hBD3
in particular has been shown to be increased in psoriatic skin
(Nomura et al., 2003) and a higher copy number of BD loci is
associated with increased susceptibility to psoriasis (Hollox
et al., 2008). However, the influence of hBD3 on innate and
adaptive immunity remains poorly understood.
The effects of hBD on human DCs have not been well
documented. One human defensin, hBD3, was originally
isolated from psoriatic skin flakes and retained antimicrobial
activity at physiological salt concentrations (Harder et al.,
2001). As hBD3 is produced primarily by keratinocytes, we
specifically studied its effect on human Langerhans cell–like
DCs (LC-DC) and skin-derived DCs. LCs have an important
role in protecting the skin against pathogens and are
remarkably plastic and responsive to environmental signals,
enabling them to functionally bridge innate and adaptive
immune responses. Under inflammatory conditions, LCs
migrate rapidly out of the skin in a CCR7-dependent manner
and move toward the draining lymph node where they can
present antigen to T cells and initiate antigen-specific
immune responses (Ohl et al., 2004). DCs with features
of LCs (LC-DCs) can be generated in vitro from human
monocytes by culture in the presence of GM-CSF and
TGF-b (Geissmann et al., 1998; Yang et al., 1999b; Guironnet
et al., 2002). LC-DCs differ from classic monocyte-derived
DCs generated by culture with GM-CSF and IL-4 and
uniquely express molecules typical of LCs, including
langerin, CCR6, and E-cadherin.
In this study, we demonstrate that hBD3 induces pheno-
typic and functional maturation of immature human LC-DCs,
and this is mediated in part by NF-kB activation. Further-
more, hBD3-stimulated LC-DCs induce strong proliferation
and IFN-g production by naive CD4þCD45RAþ T cells.
hBD3 also induced maturation/activation of primary human
skin–migratory DCs, suggesting that hBD3 is an important
contributor to cutaneous immune regulation in vivo.
RESULTS
hBD3 induces phenotypic maturation of human LC-DC
DCs with features of LCs (LC-DCs) were generated from
peripheral blood mononuclear cells by culture with GM-CSF
and TGF-b using well-described methods (Geissmann et al.,
1998; Guironnet et al., 2002). The identity of these LC-DCs
was confirmed by flow-cytometric staining for the LC markers
CD1a, E-cadherin, CCR6, and CD207 (Langerin) (Figure 1).
The LC-DCs also expressed HLA-DR, characteristic low to
moderate levels of the costimulatory molecules CD40, CD80,
CD83, and CD86, and lacked expression of the monocyte/
macrophage marker CD14 (not shown).
Maturation stimuli such as inflammatory cytokines or
TLR ligands induce the maturation and activation of DCs,
including increased cell surface expression of costimulatory
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Figure 1. Culturing human monocytes with GM-CSF and transforming
growth factor (TGF)-b1 generates Langerhans cell–like dendritic cells
(LC-DCs) that are distinctly different from DCs generated in the presence
of GM-CSF and IL-4. Human monocytes were isolated from the blood of
healthy donors by density gradient centrifugation and cultured in
serum-free AIM-V medium with rhGM-CSF and rhIL-4 or with rhGM-CSF and
rhTGF-b1 for 6 days. Cell surface expression of HLA-DR, E-cadherin,
CD1a, CCR6, and langerin was assessed by flow cytometry. In each case,
the percentage of cells considered positive for each marker is shown.
Results are representative of three separate experiments with cells
generated from different donors.
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and adhesion molecules. To evaluate the potential effect of
hBD3 stimulation on the maturation/activation of LC-DCs,
day 6, human immature LC-DCs were stimulated for 18 hours
with medium alone or with 5 mM hBD3. For comparison, we
evaluated the activation effects of TNF-a, a well-established
LC activation signal that is present at increased levels
in inflamed skin, by stimulating immature LC-DCs with
10 ngml1 TNF-a. The LC-DCs were then stained with anti-
bodies against HLA-DR, CD83, CD86, CD40, and CCR7, and
surface expression was evaluated by flow cytometry. Our
findings show that hBD3 consistently induced increased
surface expression of HLA-DR, CD83, CD86, and CCR7,
but not of CD40 (Figure 2a). In contrast, TNF-a induced
increased expression of HLA-DR on LC-DCs but did not signi-
ficantly upregulate the other maturation molecules tested. It is
noteworthy that hBD3 strongly upregulated CCR7, a crucial
lymph node–homing receptor, whereas TNF-a had no mea-
surable effect on CCR7 expression in LC-DCs. Furthermore,
the observed LC-DC maturation phenotype was specific to
hBD3 because neither hBD2 nor hBD4 matured LC-DC
(Figure 2b). To determine the optimal concentration of
hBD3, we performed a dose–response analysis using 500,
1, 2, and 5 mM concentrations of hBD3 (Figure 2c). The results
show that increasing the concentrations of hBD3 resulted
in enhanced maturation of LC-DCs as measured by the
upregulation of several costimulatory markers. These data
show that hBD3 induces phenotypic changes in LC-DCs
consistent with DC activation.
hBD3-stimulated LC-DCs migrate toward CCL19 and CCL21
To determine the functional significance of hBD3-induced
CCR7 expression, we examined the ability of hBD3-treated
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Figure 2. Human beta-defensin 3 (hBD3) induces phenotypic maturation of Langerhans cell–like dendritic cells (LC-DCs). (a) Day 6 LC-DCs were cultured
for 18 hours with medium, tumor necrosis factor (TNF)-a (10 ngml1), or hBD3 (5 mM). The surface expression of HLA-DR, CD83, CD86, CD40, and CCR7
was assessed by flow cytometry. The shaded gray histogram indicates the isotype-matched irrelevant antibody, whereas the black line represents the
antibody to the indicated protein. Numbers represent the mean fluorescence intensity (MFI) of each experiment. (b, c) Flow cytometric analysis following
overnight culture of day 6 LC-DCs with (b) 5 mM hBD2, hBD3, or hBD4, or (c) varying concentrations of hBD3 (500, 1, 2, 5 mM). The surface expression of various
markers was assessed and the MFI values plotted graphically. Results are representative of three to five experiments using cells from different donors.
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LC-DCs to migrate toward the CCR7 ligands CCL19 and
CCL21. Again, day 6 immature LC-DCs were stimulated for
18 hours with medium alone, hBD3, or with TNF-a. Chemo-
tactic migration toward CCL19 and CCL21 was measured
using an in vitro transwell system. Stimulation of LC-DCs with
hBD3, but not with TNF-a or medium, enabled significant
migration toward both CCR7 ligands across a transwell
micropore membrane (Po0.02; Figure 3). This effect appears
to be CCR7-specific, as inclusion of CCL19 with the cells in
the upper well abolishes migration toward CCL21. These data
suggest that hBD3 can promote migration and lymph node
localization of LC-DCs.
hBD3-stimulated LC-DCs polarize T cells to produce IFN-c
To determine the effect of hBD3 on the T-cell stimulatory
function of LC-DCs, we compared the ability of untreated,
TNF-a-treated, or hBD3-treated LC-DCs to activate naive
CD4þ T cells in a mixed lymphocyte reaction. Day 6
immature LC-DCs were treated for 18 hours with medium,
TNF-a, or hBD3, and then washed and incubated with allo-
geneic CD4þCD45RAþ T cells for 5 days. T-cell prolifera-
tion was determined by measuring the incorporation of
tritiated thymidine. IFN-g secretion was also evaluated by
determining the concentration of IFN-g in culture super-
natants by ELISA. Stimulation with either hBD3 or TNF-a
enabled LC-DCs to induce potent T-cell proliferation,
consistent with the well-established antigen presentation
function of activated DCs (Figure 4a; *Po0.05). However,
LC-DCs stimulated with hBD3 uniquely induce high-level
production of IFN-g by responding T cells (Figure 4b;
*Po0.031). Taken together, these data demonstrate that
hBD3 exposure induces potent antigen presentation capacity
in LC-DCs, and unlike TNF-a, hBD3 induces high levels of
IFN-g production by primed T cells, suggesting that hBD3
skews T-cell activation toward a T-helper type-1 immune
response.
hBD3-induced maturation of LC-DCs is not MyD88- or
Gi protein–coupled receptor–dependent, but is dependent on
NF-jB and mitogen-activated protein kinase (MAPK) activation
Studies have shown that hBD3 can signal through TLR1 and
TLR2 in a MyD88-dependent manner (Funderburg et al.,
2007). To determine whether MyD88-dependent TLR
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Figure 4. Human beta-defensin 3 (hBD3)-matured Langerhans cell–like dendritic cells (LC-DCs) activate naive T cells and enhance the proliferation and
IFN-c secretion of T cells in a mixed lymphocyte reaction. Day 6 LC-DCs were cultured for 18 hours with medium alone, tumor necrosis factor (TNF)-a
(10 ngml1), or with hBD3 (5 mM). Cells were then cocultured with allogeneic purified CD4þCD45RAþ T cells. (a) T cells were cultured for 3 days
at LC-DC:T-cell ratios ranging from 1:10 to 1:80. T-cell proliferation was measured by uptake of tritiated thymidine during the last 18 hours of culture.
(b) Production of IFN-g was measured by ELISA after 5 days of culture and is also shown for a range of LC-DC:T-cell ratios. Results are representative of
three separate experiments (*Po0.05).
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Figure 3. Human beta-defensin 3 (hBD3)-matured Langerhans cell–like
dendritic cells (LC-DCs) are chemotactic for the CCR7 ligands. Day 6
LC-DCs were treated for 18 hours with medium alone, tumor necrosis factor
(TNF)-a (10 ngml1), or with hBD3 (5mM). The cells were collected and added
to the upper chamber of a chemotaxis plate containing medium, CCL19
(250 ngml1), or CCL21 (250 ngml1) in the lower wells. Migration of
cells toward the chemokine was measured by counting the number of cells
migrated into the lower wells after 90minutes. Chemotactic index¼ cells
migrating toward chemokine/cells migrating toward medium. To show
specificity of chemotactic response, LC-DCs were resuspended in medium
containing CCL21 (250 ngml1), and their migration toward CCL19
(250 ngml1) chemoattractant in the lower wells was assessed (bars labeled
CCL21/CCL19). Results are representative of three separate experiments
performed in duplicate.
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signaling was required for the maturation of LC-DCs by
hBD3, we pretreated LC-DCs with an MyD88 peptide
inhibitor (100mM, 18 hours) before hBD3 treatment. The
inhibition of MyD88 signaling had no detectable effect on the
upregulation of CD86 and CCR7 in LC-DCs (Figure 5a). We
confirmed the ability of the MyD88 peptide to inhibit
lipopolysaccharide-induced maturation of LC-DCs at similar
concentrations (Figure 5b).
In addition, other studies have shown that hBDs can signal
through Gi protein–coupled receptors such as CCR2, CCR6,
or CXCR4 (Yang et al., 1999a; Feng et al., 2006; Rohrl et al.,
2010). To determine whether any of these Gi protein–coupled
receptors were involved in the maturation of LC-DCs by
hBD3, we pretreated day 6 LC-DCs with pertussis toxin for
2 hours before maturation with hBD3, and then examined
HLA-DR, CD83, CD86, and CCR7 upregulation as markers
of overall LC-DC maturation. Although there was a notable
reduction in CD86, our findings show that the blocking
of Gi protein–coupled receptors by pertussis toxin had no
significant effect on hBD3-induced HLA-DR, CD83, and
CCR7 upregulation of LC-DCs (Figure 5c).
Our recent studies have shown that the hBD3-mediated
upregulation of CCR7 in human tumors is dependent on NF-
kB and AP1 transcription factors (Mburu et al., 2011, 2012).
Indeed, these transcription factors are activated by various
inflammatory stimuli and are associated with the maturation
and survival of antigen-presenting cells. First, to determine
whether NF-kB activation was required for hBD3-induced
maturation and CCR7 upregulation, we transduced the LC-
DCs with an adenovirus vector encoding the IkBaAA
dominant-negative super repressor, or with a control, blank
adenovirus. NF-kB blockade resulted in significant inhibition
of hBD3-induced CD86 and CCR7 upregulation in LC-DCs
(Figure 5d). Second, to determine whether MAPK/AP1
activation was necessary for hBD3-mediated LC-DC matu-
ration and CCR7 upregulation, we pretreated day 6 LC-DCs
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Figure 5. Human beta-defensin 3 (hBD3) stimulation of Langerhans cell–like dendritic cells (LC-DCs) is not MyD88 or Gi protein–coupled receptor
(GiPCR) dependent but is dependent on NF-jB and mitogen-activated protein kinase (MAPK) activation. (a, b) Day 5 LC-DCs were treated overnight
with MyD88 inhibitor (100mM), followed by stimulation with (a) hBD3 (5 mM, 18 hours) or (b) lipopolysaccharide (LPS; 100 ngml1, 18 hours), and analyzed
using flow cytometry. Values represent mean fluorescence intensity in treated cells. (c) Day 6 LC-DCs were treated with pertussis toxin (200 ngml1, 2 hours),
followed by hBD3 (5 mM, 18 hours). (d) Day 5 LC-DCs were transduced with control (solid line) or IkBAA (dotted line) containing adenovirus over 24 hours,
followed by treatment with hBD3 (5 mM, 18 hours). (e) Day 6 LC-DCs were treated with PD98059 (100mM, 2 hours), followed by hBD3 (5 mM, 18 hours). Results
shown are representative of two to three experiments with cells from different donors.
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with the MAPK inhibitor PD98059 (100 mM, 2 hours),
followed by overnight stimulation with 5mM hBD3. MAPK/
AP1 inhibition resulted in a reduction in hBD3-mediated
CD86 and CCR7 upregulation in LC-DCs (Figure 5e).
Together, these data suggest that hBD3 stimulates the
maturation of LC-DCs through the NF-kB- and MAPK/AP1-
dependent pathways.
Skin-migratory DCs acquire a mature phenotype following
exposure to hBD3
We focused our studies on LC-DCs as they can be reliably
generated in sufficient quantities to allow for both phenotypic
and functional studies to be conducted. However, because
cultured cells can behave differently from primary human
cells, we collected primary human DCs that had migrated out
of skin explants (Larregina et al., 2001) to determine whether
hBD3 had a similar effect on the activation of these cells.
Skin-migratory DCs were cultured for 18 hours with medium
alone or with hBD3 (5mM, 37 1C), and expression levels of
CD86 and CCR7 were measured by flow cytometry. As seen
in our LC-DC experiments, primary skin–migratory DCs,
although already in a more mature state at baseline, showed
further phenotypic maturation following treatment with
hBD3, extending the relevance of our findings to human
cutaneous DCs (Figure 6).
DISCUSSION
Antimicrobial peptides, including BDs and cathelicidins, are
produced by epithelial cells under conditions of inflamma-
tion or infection. Their production is stimulated by exogenous
microbial danger signals, such as TLR agonists, and by
endogenous mediators of inflammation, such as TNF-a, IL-1,
IFN-g, and IL-17 (Biragyn et al., 2002; Chadebech et al.,
2003; Joly et al., 2005; Kolls et al., 2008). Indeed, such
inflammatory mediators can induce skin-resident DC matura-
tion by directly promoting the maturation of DCs, or by
inducing DC activation indirectly by stimulating keratino-
cytes to produce BDs (De Smedt et al., 1996; Rieser et al.,
1997; Berthier-Vergnes et al., 2005; Flacher et al., 2006).
Although the role of BDs in innate immunity has been well
established, their influence on acquired immune responses is
less clear. As described in the introduction, several studies
have shown that BDs can potentiate an inflammatory
response by recruiting monocytes, DCs, and T cells. How-
ever, there are recent studies using mBD14 (the mouse
homolog to hBD3) that show that BDs can have some anti-
inflammatory properties as well, through the induction of
T-regulatory cells (Semple et al., 2010, 2011; Navid et al.,
2012). However, the effects of hBD3 in skin-resident DCs
have not been specifically examined. We chose to address
this issue by investigating BD effects on DCs, critical antigen-
presenting cells capable of priming antigen-specific T-cell
responses and skewing-acquired immunity in response to
environmental stimuli. As defensins are produced primarily
in skin, we chose to study the effects of hBD3 on cultured
DCs that most closely resemble those found in skin. Using
well-established techniques, we were able to generate
and manipulate sufficient numbers of human LC-DCs from
peripheral blood precursors obtained from normal donors.
The immature LC-DCs used in our studies express the LC
markers CD1a, langerin, and E-cadherin.
Human BD3 has been shown to be chemotactic for
monocytes and memory T cells (Wu et al., 2003). We now
show that this molecule has an important role in stimulating
acquired immune responses by inducing phenotypic and
functional maturation of LC-DCs in vitro. Consequently,
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Figure 6. Human beta-defensin 3 (hBD3) induces phenotypic maturation of skin-migratory dendritic cells (DCs). Skin-migratory DCs were cultured for
18 hours in the presence or absence of hBD3 (5 mM). They were then assessed for cell surface expression of maturation markers. (a) CD86 and (b) CCR7
expression is shown in cells cultured in medium alone (solid line) and in the presence of hBD3 (dashed line). Solid histograms show staining of cells
with an isotype-matched control antibody.
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matured LC-DCs achieve the capacity to induce proliferation
and IFN-g production by naive T cells. As part of the
maturation process, hBD3-treated LC-DCs upregulate
expression of CCR7 and become responsive to the lymph
node–homing CCR7 ligands CCL19 and CCL21. Together,
our findings suggest that hBD3 may act as an endogenous
danger signal that alerts the immune system to possible
infection and mobilizes, activates, and polarizes DCs to
become effective activators of T-cell responses. Interestingly,
the extent of this hBD3-mediated maturation of LC-DCs was
much greater than that observed with TNF-a treatment.
In a mouse model, Biragyn et al. (2002) using mBD2 and
murine DCs found that mBD2 induced phenotypic matura-
tion and improved the antigen presentation function in mixed
lymphocyte reactions. Results from Biragyn et al. (2002)
study were reported as being consistent with a mechanism,
whereby mBD2 induced DC maturation via TLR4. In
contrast, cathelicidin peptides have been shown to block
TLR4-mediated activation of DCs in a murine model (Di
Nardo et al., 2007). Interestingly, studies now suggest that
hBD3 binds promiscuously to several receptors, depending
on the cell type and function. For instance, in studying the
response of human monocytes to hBD3 maturation, work by
Funderburg et al. (2007) showed that activation of TLR1/2
heterodimers was required for hBD3-induced maturation,
whereas a different group (Rohrl et al., 2010) showed that
hBD3-mediated monocyte chemotaxis is dependent on the
CCR2 receptor. In other studies, hBD1 and hBD2 have been
reported to bind to CCR6 (inducing chemotaxis; Yang et al.,
1999a), whereas hBD3 has been suggested to bind to CXCR4
(inducing downregulation of this receptor and preventing its
use by HIV as a coreceptor for T-cell infection; Feng et al.,
2006). Our findings suggest that LC-DCs do not use these
pathways as the use of a MyD88 peptide inhibitor or pertussis
toxin (an inhibitor of Gi protein–coupled receptor signaling)
had no significant effects on the maturation of LC-DCs by
hBD3. In separate studies, we investigated whether TLR5
might be involved in the hBD3-mediated effects (as flagellin-
mediated signaling is a strong inducer of hBD3 induction in
skin cells (Gerstel et al., 2009)). We found that hBD3 does
not require TLR5 for LC-DC maturation (unpublished
observations). In summary, these findings suggest that these
receptors are not involved in mediating the observed hBD3
maturation of LC-DCs. However, further work is needed to
determine which receptor(s) is/are utilized by hBD3 to
mediate LC-DC maturation.
The role of inflammatory NF-kB and MAPK/AP1 signals in
promoting the maturation of various antigen-presenting cells
has been well documented, as these transcription factors
control several genes involved in DC maturation (see Li and
Verma (2002) for review). Our studies demonstrate that
activated NF-kB is required for hBD3-induced maturation in
LC-DCs. In the presence of an IkB super-repressor, there is
significant inhibition of CD86 and CCR7 upregulation in
LC-DCs. It is interesting to note, however, that despite the
well-documented potent NF-kB-inducing capability of
TNF-a, this cytokine resulted in only a marginal upregulation
of the costimulatory markers examined in our study. This
suggests that NF-kB may well be required but is not sufficient
to fully activate the LC-DC maturation pathway, and that
other factors in the hBD3 signaling pathway are necessary to
mature LC-DCs. Indeed, these factors may include the MAPK/
AP1 pathway, which appears to be involved in the matura-
tion of LC-DCs based on our results using PD98059 (an
inhibitor of Erk-dependent MAPK/AP1 activation). Relevant
to this, our group has recently identified cooperative
transcriptional control of CCR7 expression in tumors by
hBD3, which is mediated by NF-kB and AP1 transcription
factors (Mburu et al., 2011, 2012).
Our findings have important implications for understand-
ing how immune responses are generated and regulated
in the skin, particularly in understanding inflammatory skin
diseases such as psoriasis. hBD3 has been shown to be
upregulated in psoriatic skin. Psoriasis is a classic T-helper
type 1–mediated disease, associated with high levels of T-cell
production of IFN-g (Liu et al., 2007). Further, infection of
skin or other soft tissue has been implicated in the
pathogenesis of psoriasis (Teravert, 1970). This could partly
be because of increased production of hBD3 in response to
microbial infection, which in turn induces cutaneous LC
maturation and subsequent T-cell activation and cytokine
production. hBD3 appears to be a natural adjuvant capable
of stimulating innate immunity and enhancing specific
immune responses against antigens encountered by the skin.
In summary, we have shown that hBD3 induces activation
of human LC-DCs and primary human cutaneous DCs in vitro.
Activated LC-DCs upregulate CCR7, become responsive to
the lymph node–homing chemokines CCL19 and CCL21,
prime naive T cells, and stimulate T-cell production of IFN-g.
Furthermore, the observed hBD3-induced maturation of LC-
DCs is dependent on NF-kB and MAPK/AP1 activation. These
results contribute to our understanding of the potential role of
hBD3 in the pathogenesis of inflammatory skin diseases and
demonstrate the adjuvant function of hBD3. Our findings
should be useful for the development of novel immunogens
that incorporate hBD3 and specific antigens to enhance the
immunogenicity of DC-based immunotherapies and skin-
targeted vaccines.
MATERIALS AND METHODS
Antibodies and reagents
The following cytokines and chemokines were purchased from R&D
Systems (Minneapolis, MN): rhGM-CSF, rhIL-4, rhTGF-b1, rhTNF-a,
rhCCL19, and rhCCL21. The following antibodies used for flow
cytometric analysis were purchased from BD Biosciences (San Jose,
CA): mouse anti-human CD40-PE (clone 5C3), mouse anti-human
CD83-FITC (clone HB15e), mouse anti-human CD86-PE (clone
2331), mouse anti-human CCR6-PE (clone 11A9), rat anti-human
CCR7-FITC (clone 3D12), and mouse anti-human HLA-DR-FITC
(clone L243). Phycoerythrin-conjugated mouse anti-human langerin
(CD207; clone DCGM4) was purchased from Immunotech
(Fullerton, CA). Synthetic hBD3 containing the proper disulfide
bridges was purchased from Peptides International (Louisville, KY).
The MyD88 peptide inhibitor was purchased from Imgenex
(San Diego, CA). Adenoviral constructs were obtained from the
vector core facility at the University of Pittsburgh.
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Cell culture
Buffy coats from healthy donors were obtained from the Pittsburgh
Central Blood Bank through an IRB-exempt protocol. Peripheral
blood mononuclear cells were separated over a Ficoll gradient by
centrifugation at 1400 r.p.m. for 30minutes at room temperature.
Cells were then washed three times in RPMI, and monocytes were
separated from lymphocytes using 60, 45, and 34% percoll
gradients. The monocyte layer was removed, washed in RPMI, and
then plated at a density of 106 cells per ml in serum-free AIM-V
medium supplemented with rhGM-CSF (10 ngml1)þ rhTGF-b1
(5 ngml1) for LC-DCs or with rhGM-CSF (10 ngml1)þ rhIL-4
(10 ngml1) for mDCs. Fresh cytokines were added on culture
day 3. Cells were harvested by placing at 4 1C and resuspending
in cold 1 PBS and used on days 6–7 of culture.
Flow cytometry
Flow cytometric analysis was performed using a Becton–Dickinson
FACS calibur. Staining was performed using a wash buffer of 1%
fetal bovine serum in PBS and the manufacturer’s recommended
concentration of antibody (or if no recommendations were given, a
concentration of 5mgml1 was used) to stain cells for 25minutes.
Cells were washed twice in wash buffer and fixed in 2%
paraformaldehyde in PBS before data acquisition.
Chemotaxis assay
Chemotaxis assays were performed using disposable 96-well
chemotaxis plates (Neuro Probe, Gaithersburg, MD). A volume of
30 ml of serum-free AIM-V medium alone or medium containing the
respective chemokine ligands CCL19 or CCL21 (250 ngml1) was
added to the lower wells of a 96-well plate. An 8-mm-pore
membrane was placed over the wells taking care not to trap any
air bubbles. To the top of the membrane, a 50 ml cell suspension
containing 2.5 104 LC-DCs in AIM-V was added. Cells were
allowed to migrate for 90minutes at 37 1C. The number of migrated
cells in the lower wells was determined by counting on a
hemacytometer under trypan blue staining. All assays were
performed in duplicate. Chemotactic index, a measure of relative
migration, was obtained by calculating the number of cells migrating
into chemokine-containing wells relative to that migrating into wells
containing medium only.
T-cell cytokine production and proliferation assays
LC-DCs were matured by incubation with indicated maturation
inducer(s) for 18 hours in AIM-V medium containing 5% human
AB serum at 37 1C, washed, and then counted. T cells from an
allogeneic donor (from buffy coats purchased from the Pittsburgh
Central Blood Bank) were isolated using a Percoll gradient as
described above. CD4þCD45RAþ -naive T cells were then isolated
by negative selection using magnetic beads as per the manufacturer’s
instructions (Miltenyi, Auburn, CA). For stimulation assays, various
dilutions of LC-DCs and 105 T cells were added in AIM-V at a total
volume of 200ml per well of a 96-well plate. Plates were incubated
for 5 days at 37 1C, after which supernatants were harvested and
stored at 20 1C for later use or immediately and tested for IFN-g
using commercially available ELISA-matched antibody pairs (BD
Pharmingen, San Jose, CA) as per the manufacturer’s protocol. In the
T-cell proliferation assays, T cells were stimulated as described for
cytokine production using LC-DCs that were irradiated at 2500 rads.
Proliferation was measured as a function of tritiated thymidine
uptake during the final 16 hours of a 3-day culture.
Generation of skin-migratory DCs
The generation of primary human skin–migratory DCs has been
described, and these cells have been characterized previously
(Larregina et al., 2001). In brief, residual human skin generated
following abdominoplasty was excised with a skin graft knife
(Padgett Instruments, Kansas City, MO) to generate skin explants
with a thickness of 0.3–0.5mm. These explants were then cultured,
epidermal side up, on 1-mm-pore steel meshes with RPMI 1640
supplemented with 10% heat-inactivated fetal calf serum, 20mM
Hepes, 2mM L-glutamine, 200Uml1 of penicillin–streptomycin
(Gibco-BRL, Grand Island, NY), and 20 mgml1 of gentamicin (Sigma,
St Louis, MO) at 37 1C in 5% CO2. After 72 hours, nonadherent cells
that had migrated out of the explants were collected and exposed to
hBD3 or medium for 18 hours. Analysis for markers of maturation
was performed as described above.
Statistical analysis
The data are expressed as mean±SE of two to three repeats. A two-
tailed Student’s t-test was used to calculate whether the observed
differences were statistically significant. The threshold for signifi-
cance was Po0.05.
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